Interest of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1
L. Képénékian(Hospices Civils de Lyon), P. Combemale(Centre Léon Bérard), Françoise Borson‐Chazot(Hospices Civils de Lyon), Anne‐Laure Giraudet(Centre de Recherche en Cancérologie de Lyon), Thomas Mognetti(Centre de Recherche en Cancérologie de Lyon), S. Pinson(Hôpital Edouard Herriot), Jean‐Christophe Lifante(Lyon 1 Université), C. Houzard(Hôpital Lyon Sud)
Cited by 69
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study
|Annals of Oncology|2015|257
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192